Skip to main content

Table 1 The characteristics of the patients with ankylosing spondylitis (AS), ulcerative colitis (UC), and healthy controls (HC)

From: A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin

 AS (n = 150)UC (n = 18)HC (n = 17)
Women/men, n (%)68 (45.3)/82 (54.7)8 (44.4)/10 (55.6)6 (35.5)/11 (64.7)
Age, years55.5 (46–67)30.5 (27–39)22 (21–31)
AS symptom duration, years28.5 (18–39)  
HLAB27 positive, n (%)127 (84.7)  
BAS-G, score2.8 (1.5–5.9)  
ASDAS-CRP, score2.1 (1.3–1.7)  
BASDAI, score3.2 (1.8–5.2)  
BASFI, score2.3 (1.1–4.1)  
BASMI, score3.4 (2.4–4.6)  
ESR, mm/h8 (4–14)  
CRP, mg/L3 (1–6)5 (3.5–16.5)1 (1–1)
Fecal calprotectin, mg/kg80 (0–190)606 (29–10,320)All < 15
Patients on NSAIDs, n (%)115 (76.7)00
 - Daily use of NSAIDs61 (40.7)  
 - On-demand use of NSAIDs54 (36.0)  
On TNFi all, n (%)35 (23.3)0N.A.
 - TNFi in monotherapy16 (10.7)  
 - TNFi + methotrexate19 (12.7)  
On DMARD monotherapy16 (10.7)0N.A.
 - Methotrexate9 (6.0)  
 - Sulfasalazine7 (4.7)  
  1. Data is presented as median (interquartile range) or number (%)
  2. ASDAS-CRP Ankylosing Spondylitis Disease Activity Score based on CRP, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BAS-G Bath Ankylosing Spondylitis patient Global score, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DMARD disease modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, NSAID non-steroidal anti-inflammatory drug, TNFi tumor necrosis factor inhibitor